Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0869 in Major Depressive Disorder
NCT00034944Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2002
- Primary completion
- Dec 2003
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Drugs
- aprepitant
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in major depressive disorder (MDD) (3 arms), sponsored by Merck & Co. Primary endpoints: Hamilton Rating Scale for Depression 17-Item at 8 weeks and Tolerability. Started Jan 2002; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
MK0869 Dose 1
MK0869 (aprepitant) at Dose 1
MK0869 Dose 2
MK0869 (aprepitant) at Dose 2
Placebo
Placebo comparator
03
Who it enrols
Patients with Major Depressive Disorder.
04
Endpoints
Primary
Hamilton Rating Scale for Depression 17-Item
Tolerability
Secondary
Clinical Global Impressions-Improvement
HAMD-17 Response Rate
Beyond the preview
Go deeper on NCT00034944.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034944.